invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited, focused on R&D and business development activities outside of China, and F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy, today announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. Source: F Star press release 23/6/2022